NKTR Stock Plunges on Rezpegaldesleukin Data; William Blair Maintains Durability View
Nektar Therapeutics (NKTR) shares dropped 21% on Thursday after the company presented new response rate data for its experimental skin drug, rezpegaldesleukin. While the drug reportedly maintained efficacy after treatment stopped, the new response rates were modest and derived from small patient groups, putting the stock on track for its worst daily performance in over three years. William Blair analysts, however, still see a durability edge for the drug.
Shares of Nektar Therapeutics (NKTR) dropped 21% on Thursday even as the company said its experimental skin drug, rezpegaldesleukin, continued to work after treatment ended. The latest response rates were modest and came from small patient groups. The stock was on track for its…